BG
KZR

Bellevue Group’s Kezar Life Sciences KZR Stock Holding History

Bellevue Group’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,000
Closed -$24.5K – 161
2023
Q2 		$24.5K Hold
1,000
– – ﹤0.01% 154
2023
Q1 		$31.3K Sell
1,000
-302,100
-100% -$17.5M ﹤0.01% 155
2022
Q4 		$21.3M Hold
303,100
– – 0.28% 81
2022
Q3 		$26.1M Sell
303,100
-400
-0.1% -$38.9K 0.37% 70
2022
Q2 		$25.1M Sell
303,500
-163,315
-35% -$14.4M 0.35% 76
2022
Q1 		$77.6M Sell
466,815
-25,000
-5% -$3.59M 0.9% 40
2021
Q4 		$82.2M Buy
491,815
+38,500
+8% +$4.35M 0.85% 38
2021
Q3 		$39.2M Hold
453,315
– – 0.4% 79
2021
Q2 		$24.6M Hold
453,315
– – 0.24% 100
2021
Q1 		$27M Hold
453,315
– – 0.29% 93
2020
Q4 		$23.7M Hold
453,315
– – 0.27% 91
2020
Q3 		$21.9M Buy
453,315
+29,121
+7% +$1.39M 0.3% 85
2020
Q2 		$22M Buy
424,194
+72,305
+21% +$3.65M 0.31% 75
2020
Q1 		$15.3M Buy
351,889
+196,822
+127% +$8.01M 0.3% 68
2019
Q4 		$6.22M Buy
155,067
+32,015
+26% +$985K 0.1% 108
2019
Q3 		$4.04M Hold
123,052
– – 0.08% 117
2019
Q2 		$9.49M Buy
+123,052
New +$19.1M 0.16% 89

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bellevue Group's KZR Position: Q3 2023 in Review

Bellevue Group sold out of Kezar Life Sciences (KZR) in Q3 2023, closing a stake of 1,000 shares — an estimated $24.5K sold.

Bellevue Group first reported a position in KZR in Q2 2019 and held it in 17 quarters. The position peaked at $82.2M in Q4 2021. 82 funds tracked by Wall St. Rank hold KZR as of Q3 2023.

  • Bellevue Group reported no remaining Kezar Life Sciences position as of Q3 2023 after selling out during the quarter.
  • Bellevue Group sold 1,000 Kezar Life Sciences shares in Q3 2023, an estimated $24.5K.
  • Bellevue Group first reported a position in Kezar Life Sciences in Q2 2019 and held it in 17 quarters.
  • Bellevue Group's Kezar Life Sciences position peaked at $82.2M in Q4 2021.
  • 82 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2023.

Based on Bellevue Group's 13F filing for Q3 2023, filed 14 Nov 2023.